Cancer phase I clinical trials: efficient dose escalation with overdose control.
about
Early phase clinical trials to identify optimal dosing and safetyA modified toxicity probability interval method for dose-finding trials.Ceritinib in ALK-rearranged non-small-cell lung cancer.Identifying a maximum tolerated contour in two-dimensional dose finding.Continual reassessment method for partial ordering.Dose-finding design for multi-drug combinations.Continual Reassessment and Related Dose-Finding DesignsDesigns for single- or multiple-agent phase I trials.Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.Using Data Augmentation to Facilitate Conduct of Phase I-II Clinical Trials with Delayed Outcomes.A practical design for a dual-agent dose-escalation trial that incorporates pharmacokinetic data.Towards using a full spectrum of early clinical trial data: a retrospective analysis to compare potential longitudinal categorical models for molecular targeted therapies in oncology.Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma.A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignanciesPhase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.Developing a Bayesian adaptive design for a phase I clinical trial: a case study for a novel HIV treatment.Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials.A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trialsAdaptive dose-finding studies: a review of model-guided phase I clinical trials.Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors.Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control.Learning from previous responses in phase I dose-escalation studiesWhat does a modified-Fibonacci dose-escalation actually correspond to?A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosisCompeting designs for phase I clinical trials: a review.Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumorsA first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies.Escalation with overdose control using time to toxicity for cancer phase I clinical trials.A likelihood-based approach for computing the operating characteristics of the 3+3 phase I clinical trial design with extensions to other A+B designs.Adaptive clinical trial designs in oncology.Advances in Statistical Approaches Oncology Drug Development.Choice of designs and doses for early phase trials.Incorporating individual and collective ethics into phase I cancer trial designs.Innovative Clinical Trial Designs: Toward a 21st-Century Health Care SystemIncorporating lower grade toxicity information into dose finding designs.Monitoring late-onset toxicities in phase I trials using predicted risksAmerican Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment.Adaptive Isotonic Estimation of the Minimum Effective and Peak Doses in the Presence of Covariates.
P2860
Q26865076-3FC70D73-E145-45E7-A6A0-2D073B95E0D7Q27323581-7D252AB8-18D6-482E-9E79-DCC9A0D72ACEQ27852989-9888B368-6616-40BB-A9E3-0A6908D1C8D4Q30277277-9B358C8C-EDFE-49AC-9615-8BE4329B0C84Q30423577-6790B327-54D0-41EE-988C-C91AF131A233Q30424392-9C011C44-73D0-4CE0-AAE6-79BED7F1287BQ30431500-C377E3F0-51B9-4E80-AA5C-40129B4E324EQ30434355-64A8F304-DE57-4626-A207-7F52D3AE87A6Q30757656-591FB47A-B8E0-4902-B272-0180F92512B7Q30868533-B039D6F5-1437-45DC-8F7D-14B8BEF8140BQ30916465-4C99D244-B3A9-4852-8FF8-15172D6B2B1DQ30968729-ECD91B14-51EA-465A-987C-984F4FDA5BFEQ33397545-37A79C58-FC04-4B51-AD6D-6B55AEB18C32Q33405318-AE55E600-B5C9-45EF-8FCB-AFE14DE2BAF9Q33405714-18C4C206-2D85-42E1-8C08-AC63145CA7FDQ33626194-7648957D-C64A-48F3-A0C0-E82102EF09A6Q33714319-D802ECFE-41D2-48A2-9B74-E2D7FC91CB95Q33772533-70198F88-E070-4CD2-91E4-A44F271873DDQ33817421-AD0C8664-4D4D-46AA-8B7E-04D5D8EFDEE4Q33945668-3DBA812D-0355-4CE6-9FF5-DC66F3874A24Q34001009-74C5C493-ECC6-458C-87C7-657A23BC8842Q34085148-B44DFC11-E3EA-4554-B3A4-B6C43039B9F3Q34143140-7E533A4A-7511-40F7-8493-578FC9387C5EQ34308804-1C1386AB-CB7A-404F-A372-C28267550AAEQ34348422-41492834-D965-458F-BBC7-D8B2B92FFDFFQ34553682-50F91321-C977-4C18-B0B6-D6DF7AD4D0AFQ34849945-57F00A6D-FFDC-495E-B407-A8639D896A4EQ35051964-E6C641FD-556E-400D-AE9E-4EE265941A39Q35098333-F8D2C7A9-6B4B-459C-AC30-A0E65D557534Q35129807-0B3853C4-ED93-448E-ABC7-78880F183493Q35132415-43AB9ACD-98F2-4B71-8D94-6F6F5AE71DC2Q35206844-AB9A5AF3-111A-4882-BE84-AEAF5942BE7AQ35565672-E3965E6B-C629-49A5-90BD-B6191221F947Q35775310-142B7863-5F02-445F-9DEB-C02326FBCA06Q35797245-75274BD4-41D0-4F0E-B71F-90D8295AAFD3Q35797280-4800BF89-CD1D-4D0D-A940-6FB4C8113CF6Q35800784-50D2868D-3B2F-4D19-B646-CBF92AF60EAAQ35804231-88730C8D-C1EB-4579-ACFF-5C5FF8901EA6Q35894574-4E67FB28-068F-41D6-8830-B3EA778FDB0CQ36033877-80E592B5-9078-4F1C-9A5E-D911D4878D10
P2860
Cancer phase I clinical trials: efficient dose escalation with overdose control.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Cancer phase I clinical trials: efficient dose escalation with overdose control.
@en
Cancer phase I clinical trials: efficient dose escalation with overdose control.
@nl
type
label
Cancer phase I clinical trials: efficient dose escalation with overdose control.
@en
Cancer phase I clinical trials: efficient dose escalation with overdose control.
@nl
prefLabel
Cancer phase I clinical trials: efficient dose escalation with overdose control.
@en
Cancer phase I clinical trials: efficient dose escalation with overdose control.
@nl
P2093
P1476
Cancer phase I clinical trials: efficient dose escalation with overdose control.
@en
P2093
P304
P356
10.1002/(SICI)1097-0258(19980530)17:10<1103::AID-SIM793>3.0.CO;2-9
P407
P577
1998-05-01T00:00:00Z